OCUGEN, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
OCUGEN, INC. (OCGN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 691.75 thousand shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2019-03-22
- OCUGEN, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2018 was 691.75K shares.
- OCUGEN, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 132.24K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|
| 2018-12-31 | 691.75K shares 10-K · filed 2019-03-22 | |
| 2018-09-30 | 792.20K shares 10-Q · filed 2018-11-08 | |
| 2016-12-31 | 132.24K shares 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |